Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2009. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in beneficial interests in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific share transaction rather than a financial performance report.
Material Changes
The only material change disclosed is the acquisition of a beneficial interest by Mr. S M Bicknell. On July 6, 2009, he acquired 12 Ordinary shares through the re-investment of dividends under a Personal Equity Plan at a price of £10.63 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. It strictly adheres to the Disclosure and Transparency Rule 3.1.4R(1)(a) regarding the notification of the director's transaction.
Key Facts for Investor Verification
- Transaction Date: July 6, 2009
- Individual: Mr. S M Bicknell
- Shares Acquired: 12 Ordinary shares
- Acquisition Method: Dividend re-investment via Personal Equity Plan
- Price per Share: £10.63
- Notification Date: July 7, 2009